Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HRMY

STRONG BUYAPPROVE

Harmony Biosciences Holdings, Inc. · Healthcare · United States · $2.1B · Avg Vol: $29M/d

99
StockRank
Get insider-trade alerts
Q
78
V
70
M
66
P/E (TTM)
13.6x
ROE
17.9%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
$50M →
AI CONVICTION THESIS

Harmony Biosciences generates strong cash flow from its marketed narcolepsy therapy, runs a net-cash balance sheet and has a good quality score (Q78), and forward-EPS consensus has been revised up 7.8% over roughly four weeks. Nothing adverse is known on accounting, solvency or governance. Rising consensus alongside profitable commercial operations is the supportive evidence.

COMPANY DESCRIPTION

Harmony Biosciences Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from rare neurological diseases. With its flagship product WAKIX for narcolepsy already commercialized, the company establishes a strong market position by addressing significant unmet medical needs within niche neurological disorder markets.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue437.9M582.0M714.7M868.5M25.6%899.1M1.0B1.2B15.4%
EPS3.072.172.562.76-3.5%2.463.454.6129.3%
Shares59.6M56.8M57.1M57.7M-3.2%57.9M———
Debt191.6M193.6M179.3M163.7M-5.1%164.6M———
Equity402.8M467.0M659.2M870.2M29.3%————
Op CF144.5M219.4M219.8M348.2M34.1%342.0M———
Inv CF-141.8M-46.4M-67.5M-39.6M—————
Fin CF6.8M-105.6M-11.0M-9.0M—————
Loading 1Y...
PRICE (1Y)+4.0%
32.2033.7235.2336.7438.26Jun 5Jun 29Jul 20
SMA 50SMA 200
Close
$33.50
RSI (14)
40.7
52W High
$40.87
From 52W High
0.8%

SCORE BREAKDOWN

Quality
78
ROIC
22.5%93.1
ROE
17.9%86.7
GP/Assets
54.1%90.3
Op. Margin
17.3%79.0
FCF/Assets
11.8%90.1
Piotroski
548.8
Int. Cover
15.7x66.5
D/E Ratio
0.18x52.6
Current Ratio
3.58x60.5
Value
70
P/E (TTM)
13.6x78.8
EV/EBITDA
6.8x84.2
P/FCF
13.7x75.8
P/B
2.1x57.3
P/S
2.2x65.6
Div Yield
—N/A
Momentum
66
52W High %
82%72.6
RS 6M
-16%53.5
SMA 50/200
1.02x69.8
EPS Rev 4W
+7.8%95.1
EPS Rev 12W
+5.2%78.7
EPS Improve
+145%82.5
Q Growth
-29%18.3

FUNDAMENTALS

Market Cap
$2.1B
P/E (Forward)
5.6x
Gross Margin
76.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRMY are excluded.

TickerCompanyMkt CapStockRankSignal
HRMYHarmony Biosciences Holdings, Inc.(you)$2.1B99STRONG BUY
INVAInnoviva, Inc.$1.7B97STRONG BUY
CPRXCatalyst Pharmaceuticals, Inc.$3.9B100STRONG BUY
RIGLRigel Pharmaceuticals, Inc.$716M98STRONG BUY
CRMDCorMedix Inc.$616M98STRONG BUY
ZVRAZevra Therapeutics, Inc.$799M88STRONG BUY
PBYIPuma Biotechnology, Inc.$413M97STRONG BUY
HALOHalozyme Therapeutics, Inc.$8.9B91STRONG BUY
VCELVericel Corporation$2.4B64HOLD
ABUSArbutus Biopharma Corporation$905M77BUY

Peer medians: ROE -21.2% · P/E 27.9x · Gross margin 49.6%

Harmony Biosciences Holdings, Inc. (HRMY) — Stock Score Summary

Harmony Biosciences Holdings, Inc. (HRMY) has a MoatMap StockRank of 99/100 based on Quality (78/100), Value (70/100), and Momentum (66/100) factor scores. The current signal is STRONG BUY. Harmony Biosciences generates strong cash flow from its marketed narcolepsy therapy, runs a net-cash balance sheet and has a good quality score (Q78), and forward-EPS consensus has been revised up 7.8% over roughly four weeks. Nothing adverse is known on accounting, solvency or governance. Rising consensus alongside profitable commercial operations is the supportive evidence.

Harmony Biosciences Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients suffering from rare neurological diseases. With its flagship product WAKIX for narcolepsy already commercialized, the company establishes a strong market position by addressing significant unmet medical needs within niche neurological disorder markets.

Key Financial Metrics

Price$33.50
Market Cap$2.1B
P/E (TTM)13.62
P/E (Forward)5.57
Price/Book2.13
Return on Equity17.9%
Return on Invested Capital22.5%
Debt/Equity0.18x
Gross Margin76.5%
Operating Margin17.3%
Revenue Growth16.6%
Free Cash Flow$150M

Harmony Biosciences Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Harmony Biosciences Holdings, Inc.’s (HRMY) StockRank?
MoatMap’s StockRank for Harmony Biosciences Holdings, Inc. (HRMY) is 99/100, with a Strong Buy signal. It is a composite of Quality (78), Value (70), and Momentum (66) factor ranks across MoatMap’s 20,000+ stock universe.
Does Harmony Biosciences Holdings, Inc. have an economic moat?
Harmony Biosciences Holdings, Inc. (HRMY) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Harmony Biosciences Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Harmony Biosciences Holdings, Inc. (HRMY) is Strong Buy, based on a StockRank of 99/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Harmony Biosciences Holdings, Inc. in?
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksHRMY deep dive reportAI ChampionsHow we score stocksSense-check another stock